199 related articles for article (PubMed ID: 25271780)
1. pH-triggered echogenicity and contents release from liposomes.
Nahire R; Hossain R; Patel R; Paul S; Meghnani V; Ambre AH; Gange KN; Katti KS; Leclerc E; Srivastava DK; Sarkar K; Mallik S
Mol Pharm; 2014 Nov; 11(11):4059-68. PubMed ID: 25271780
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells.
Nahire R; Haldar MK; Paul S; Ambre AH; Meghnani V; Layek B; Katti KS; Gange KN; Singh J; Sarkar K; Mallik S
Biomaterials; 2014 Aug; 35(24):6482-97. PubMed ID: 24797878
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells.
Ishida T; Kirchmeier MJ; Moase EH; Zalipsky S; Allen TM
Biochim Biophys Acta; 2001 Dec; 1515(2):144-58. PubMed ID: 11718670
[TBL] [Abstract][Full Text] [Related]
5. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
Shroff K; Kokkoli E
Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin.
Mamasheva E; O'Donnell C; Bandekar A; Sofou S
Mol Pharm; 2011 Dec; 8(6):2224-32. PubMed ID: 21899300
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor activity of combined lipid bubble ultrasound and anticancer drugs in gynecological cervical cancers.
Yamaguchi K; Matsumoto Y; Suzuki R; Nishida H; Omata D; Inaba H; Kukita A; Tanikawa M; Sone K; Oda K; Osuga Y; Maruyama K; Fujii T
Cancer Sci; 2021 Jun; 112(6):2493-2503. PubMed ID: 33793049
[TBL] [Abstract][Full Text] [Related]
8. Significantly enhanced tumor cellular and lysosomal hydroxychloroquine delivery by smart liposomes for optimal autophagy inhibition and improved antitumor efficiency with liposomal doxorubicin.
Wang Y; Shi K; Zhang L; Hu G; Wan J; Tang J; Yin S; Duan J; Qin M; Wang N; Xie D; Gao X; Gao H; Zhang Z; He Q
Autophagy; 2016 Jun; 12(6):949-62. PubMed ID: 27123811
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound enhanced matrix metalloproteinase-9 triggered release of contents from echogenic liposomes.
Nahire R; Paul S; Scott MD; Singh RK; Muhonen WW; Shabb J; Gange KN; Srivastava DK; Sarkar K; Mallik S
Mol Pharm; 2012 Sep; 9(9):2554-64. PubMed ID: 22849291
[TBL] [Abstract][Full Text] [Related]
11. Aptamer-based liposomes improve specific drug loading and release.
Plourde K; Derbali RM; Desrosiers A; Dubath C; Vallée-Bélisle A; Leblond J
J Control Release; 2017 Apr; 251():82-91. PubMed ID: 28238787
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin.
Bandekar A; Karve S; Chang MY; Mu Q; Rotolo J; Sofou S
Biomaterials; 2012 Jun; 33(17):4345-52. PubMed ID: 22429980
[TBL] [Abstract][Full Text] [Related]
13. Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin.
Farasat A; Rahbarizadeh F; Ahmadvand D; Ranjbar S; Khoshtinat Nikkhoi S
J Liposome Res; 2019 Mar; 29(1):53-65. PubMed ID: 29621912
[TBL] [Abstract][Full Text] [Related]
14. A Multifunctional Lipid Incorporating Active Targeting and Dual-Control Release Capabilities for Precision Drug Delivery.
Liu C; Ewert KK; Yao W; Wang N; Li Y; Safinya CR; Qiao W
ACS Appl Mater Interfaces; 2020 Jan; 12(1):70-85. PubMed ID: 31774266
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.
Gu X; Majumder J; Taratula O; Kuzmov A; Garbuzenko O; Pogrebnyak N; Minko T
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791582
[TBL] [Abstract][Full Text] [Related]
16. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery.
Lee RJ; Wang S; Turk MJ; Low PS
Biosci Rep; 1998 Apr; 18(2):69-78. PubMed ID: 9743475
[TBL] [Abstract][Full Text] [Related]
17. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
[TBL] [Abstract][Full Text] [Related]
18. Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice.
Wang H; Zheng M; Gao J; Wang J; Zhang Q; Fawcett JP; He Y; Gu J
Talanta; 2020 Feb; 208():120358. PubMed ID: 31816795
[TBL] [Abstract][Full Text] [Related]
19. Polymer-coated echogenic lipid nanoparticles with dual release triggers.
Nahire R; Haldar MK; Paul S; Mergoum A; Ambre AH; Katti KS; Gange KN; Srivastava DK; Sarkar K; Mallik S
Biomacromolecules; 2013 Mar; 14(3):841-53. PubMed ID: 23394107
[TBL] [Abstract][Full Text] [Related]
20. pH sensitive liposomes delivering tariquidar and doxorubicin to overcome multidrug resistance of resistant ovarian cancer cells.
Xia Y; Fang M; Dong J; Xu C; Liao Z; Ning P; Zeng Q
Colloids Surf B Biointerfaces; 2018 Oct; 170():514-520. PubMed ID: 29960952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
